the core of our corporate values
Revenue rose 31.1% to RMB 632 million, while net profit increased 47.8% to RMB 179 million HANGZHOU, China, August 20, 2026 — Zylox-Tonbridge Medical Technology Co., Ltd. (HKEX: 2190, “Zylox-Tonbrid...
Zylox-Tonbridge's first residential summer camp for employees' children combined sports, educational visits, and group living in a six-day program to foster independence, curiosity, and teamwo...
HANGZHOU, China, June 8, 2026 -- Zylox-Tonbridge Medical Technology Co., Ltd. (HKEX: 2190; "Zylox-Tonbridge" or the "Company"), a Hong Kong-listed medical technology company focuse...
HANGZHOU, China, March 17, 2026 -- Zylox-Tonbridge Medical Technology Co., Ltd. (HKEX: 2190, “Zylox-Tonbridge” or the “Company”) today announced its annual results for the year ended December 31, ...
Hong Kong, January 29, 2026 — Zylox-Tonbridge Medical Technology Co., Ltd. (HKEX: 2190, the “Company” or “Zylox-Tonbridge”) today announced a positive profit alert for the fiscal year ended Decem...
Marks a major milestone in Zylox-Tonbridge’s long-term commitment to global expansionBuilds an integrated global commercialization platform to accelerate Zylox-Tonbridge’s adoption of innovative va...